^
    Back
    Association details:
    Biomarker:PD-1 overexpression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

    Published date:
    11/06/2019
    Excerpt:
    PD1 and TIGIT upregulation and co-expression were more common in progressing patients compared to non-progressors (Figure 2).
    DOI:
    10.1182/blood-2019-125931